INSP
Inspire Medical Systems Inc
$
91.750
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
93.3625
Open
92.910
VWAP
91.91
Vol
662.87K
Mkt Cap
2.71B
Low
91.380
Amount
60.92M
EV/EBITDA(TTM)
46.83
Total Shares
29.71M
EV
2.45B
EV/OCF(TTM)
20.84
P/S(TTM)
3.26
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
224.52M
+11.53%
0.142
+42.35%
264.66M
+10.4%
0.674
-41.41%
221.40M
+8.96%
-0.158
-126.27%
Estimates Revision
The market is revising Downward the revenue expectations for Inspire Medical Systems, Inc. (INSP) for FY2025, with the revenue forecasts being adjusted by -4.71% over the past three months. During the same period, the stock price has changed by -35.91%.
Revenue Estimates for FY2025
Revise Downward
-4.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-61.89%
In Past 3 Month
Stock Price
Go Down
-35.91%
In Past 3 Month
18 Analyst Rating
64.03% Upside
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 150.50 USD with a low forecast of 82.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
9 Hold
0 Sell
Moderate Buy
64.03% Upside
Current: 91.750
Low
82.00
Averages
150.50
High
255.00
64.03% Upside
Current: 91.750
Low
82.00
Averages
150.50
High
255.00
Leerink
Mike Kratky
Market Perform
downgrade
$116 -> $97
2025-08-15
Reason
Leerink
Mike Kratky
Price Target
$116 -> $97
2025-08-15
downgrade
Market Perform
Reason
Leerink analyst Mike Kratky lowered the firm's price target on Inspire Medical to $97 from $116 and keeps a Market Perform rating on the shares in the wake of Inspire's disappointing Q2 results. With the stock trading near trough valuation levels following significant recent and year-to-date underperformance, Inspire looks increasingly attractive at current levels, the firm says. However, Leerink continues to see a balanced risk/reward skew with potentially structural fundamental headwinds offsetting this undemanding valuation.
KeyBanc
Overweight -> Sector Weight
downgrade
2025-08-05
Reason
KeyBanc
Price Target
2025-08-05
downgrade
Overweight -> Sector Weight
Reason
KeyBanc downgraded Inspire Medical to Sector Weight from Overweight without a price target. The firm says its previous share thesis is "impaired" with the magnitude of the company's 2025 guidance revisions. Inspire's near- to mid-term visibility "appears incrementally uncertain" due to several new and existing headwinds, the analyst tells investors in a research note. KeyBanc adds that the company now plans to increase direct-to-consumer spend at a rate above expected sales growth.
JPMorgan
Robbie Marcus
Overweight -> Neutral
downgrade
$195 -> $110
2025-08-05
Reason
JPMorgan
Robbie Marcus
Price Target
$195 -> $110
2025-08-05
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Robbie Marcus downgraded Inspire Medical to Neutral from Overweight with a price target of $110, down from $195. The company's Q2 update was "disappointing" with a significant cut to 2025 guidance, the analyst tells investors in a research note. The firm believes investors will struggle to separate Inspire's logistics and execution issues from underlying demand issues. It cites uncertain demand trends for the Inspire V launch and execution issues for the downgrade.
Truist
Buy
to
Hold
downgrade
$190 -> $125
2025-08-05
Reason
Truist
Price Target
$190 -> $125
2025-08-05
downgrade
Buy
to
Hold
Reason
Truist downgraded Inspire Medical to Hold from Buy with a price target of $125, down from $190. The firm was braced for a guidance cut, but it was bigger than expected and a lower EPS outlook reduces the stock valuation floor, the analyst tells investors in a post-earnings note. A third Inspire V delay raises execution issues amid other potential headwinds, including GLP1 trialing, coming competition and constrained capacity, the analyst added.
Stifel
Hold
downgrade
$175 -> $140
2025-08-05
Reason
Stifel
Price Target
$175 -> $140
2025-08-05
downgrade
Hold
Reason
Stifel lowered the firm's price target on Inspire Medical to $140 from $175 and keeps a Hold rating on the shares. With 2025 revenue stepping down, partially as a function of INSP V facility activations lagging, management remains upbeat that some of its current issues are transitory and is pointing to revenue growth accelerating next year, but the firm remains cautious and lowers its "already Street-low 2026 estimate," the analyst tells investors in a post-earnings note.
UBS
Danielle Antalffy
Buy
downgrade
$270 -> $230
2025-08-05
Reason
UBS
Danielle Antalffy
Price Target
$270 -> $230
2025-08-05
downgrade
Buy
Reason
UBS analyst Danielle Antalffy lowered the firm's price target on Inspire Medical to $230 from $270 and keeps a Buy rating on the shares. A slew of headwinds drove the guidance revision lower by more than expected, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Inspire Medical Systems Inc (INSP.N) is 97.38, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Inspire Medical Systems Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.08
Current PE
97.38
Overvalued PE
220.15
Undervalued PE
-224.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-35.74
Current EV/EBITDA
14.45
Overvalued EV/EBITDA
136.54
Undervalued EV/EBITDA
-208.03
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
13.65
Current PS
2.86
Overvalued PS
21.56
Undervalued PS
5.75
Financials
Annual
Quarterly
FY2025Q2
YoY :
+10.82%
217.09M
Total Revenue
FY2025Q2
YoY :
-165.03%
-3.32M
Operating Profit
FY2025Q2
YoY :
-136.68%
-3.59M
Net Income after Tax
FY2025Q2
YoY :
-137.50%
-0.12
EPS - Diluted
FY2025Q2
YoY :
-49.38%
-6.31M
Free Cash Flow
FY2025Q2
YoY :
-0.87%
84.03
Gross Profit Margin - %
FY2025Q2
YoY :
-836.57%
9.87
FCF Margin - %
FY2025Q2
YoY :
-133.00%
-1.65
Net Margin - %
FY2025Q2
8.08
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.2M
USD
3
6-9
Months
4.8M
USD
3
0-12
Months
1.9M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
15.3K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
60.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
474.5K
Volume
Months
6-9
4
961.7K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.2M
USD
3
6-9
Months
4.8M
USD
3
0-12
Months
1.9M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
15.3K
USD
Months
INSP News & Events
Events Timeline
2025-08-26 (ET)
2025-08-26
16:34:47
Inspire Medical Supports FY25 EPS Forecast of 40c-50c, While Consensus Expects 86c
2025-08-26
16:33:51
Inspire Medical confirms FY25 EPS forecast of 40c-50c, while consensus stands at 86c.
2025-08-26
16:32:10
Inspire Medical reveals CFO Rick Buchholz is leaving the company.
Sign Up For More Events
Sign Up For More Events
News
7.0
08-25GlobenewswireInvestor Notice: Pomerantz Law Firm Probes Allegations for Inspire Medical Systems, Inc. Shareholders - INSP
7.0
08-21GlobenewswireInvestor Notice: Pomerantz Law Firm Probes Allegations for Inspire Medical Systems, Inc. Shareholders - INSP
7.0
08-20GlobenewswireBragar Eagel & Squire, P.C. Launches Investigation into Nutex, Anika, Fluor, and Inspire Medical, Urging Investors to Reach Out to the Firm
Sign Up For More News
People Also Watch
BIPC
Brookfield Infrastructure Corp
40.320
USD
+1.41%
MGY
Magnolia Oil & Gas Corp
24.140
USD
-0.94%
NSIT
Insight Enterprises Inc
126.690
USD
-3.62%
MAIN
Main Street Capital Corp
64.630
USD
+0.98%
FFIN
First Financial Bankshares Inc
37.630
USD
+2.12%
INTA
Intapp Inc
45.040
USD
+3.30%
FRSH
Freshworks Inc
13.180
USD
-2.87%
GXO
GXO Logistics Inc
53.260
USD
+0.15%
AROC
Archrock Inc
24.400
USD
+1.58%
GTES
Gates Industrial Corporation PLC
25.890
USD
+1.17%
FAQ
What is Inspire Medical Systems Inc (INSP) stock price today?
The current price of INSP is 91.75 USD — it has decreased -1.26 % in the last trading day.
What is Inspire Medical Systems Inc (INSP)'s business?
What is the price predicton of INSP Stock?
What is Inspire Medical Systems Inc (INSP)'s revenue for the last quarter?
What is Inspire Medical Systems Inc (INSP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Inspire Medical Systems Inc (INSP)'s fundamentals?
How many employees does Inspire Medical Systems Inc (INSP). have?